Medpace Corporate

In July 2026, the third Alport Research Hub Symposium took place at the Institute of Child Health in London. Organized by Kidney Research UK, this symposium brought together preclinical researchers, medical doctors, representatives from patient advocacy associations and pharmaceutical companies to discuss the latest advances in Alport syndrome research. Medpace was represente...

Despite the term “rare”, rare diseases collectively affect an estimated 300 million people worldwide and present significant clinical development challenges. At the same time, advances in therapeutic science, innovative trial designs, and evolving regulatory frameworks continue to reshape the rare disease landscape. Beyond the science, rare disea...

As precision medicine continues to reshape drug development, molecular and genomic testing have become essential for understanding disease biology, identifying biomarkers, and evaluating therapeutic response. At Medpace’s central laboratories, our molecular team supports Sponsors with a broad range of genomic and molecular testing capabilities, from targeted PCR assays to n...